<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35743175</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>16</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>EST79232 and EST79376, Two Novel Sigma-1 Receptor Ligands, Exert Neuroprotection on Models of Motoneuron Degeneration.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6737</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23126737</ELocationID><Abstract><AbstractText>Motor neuron diseases (MNDs) include sporadic and hereditary neurological disorders characterized by progressive degeneration of motor neurons (MNs). Sigma-1 receptor (Sig-1R) is a protein enriched in MNs, and mutations on its gene lead to various types of MND. Previous studies have suggested that Sig-1R is a target to prevent MN degeneration. In this study, two novel synthesized Sig-1R ligands, coded EST79232 and EST79376, from the same chemical series, with the same scaffold and similar physicochemical properties but opposite functionality on Sig-1R, were evaluated as neuroprotective compounds to prevent MN degeneration. We used an in vitro model of spinal cord organotypic cultures under chronic excitotoxicity and two in vivo models, the spinal nerve injury and the superoxide dismutase 1 (SOD1)<sup>G93A</sup> mice, to characterize the effects of these Sig-1R ligands on MN survival and modulation of glial reactivity. The antagonist EST79376 preserved MNs in vitro and after spinal nerve injury but was not able to improve MN death in SOD1<sup>G93A</sup> mice. In contrast, the agonist EST79232 significantly increased MN survival in the three models of MN degeneration evaluated and had a mild beneficial effect on motor function in SOD1<sup>G93A</sup> mice. In vivo, Sig-1R ligand EST79232 had a more potent effect on preventing MN degeneration than EST79376. These data further support the interest in Sig-1R as a therapeutic target for neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gaja-Capdevila</LastName><ForeName>N&#xfa;ria</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0028-570X</Identifier><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 01893 Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>Neus</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 01893 Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeste</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Welab Barcelona, Parc Cient&#xed;fic Barcelona, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinoso</LastName><ForeName>Raquel F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Welab Barcelona, Parc Cient&#xed;fic Barcelona, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgue&#xf1;o</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Welab Barcelona, Parc Cient&#xed;fic Barcelona, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montero</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Welab Barcelona, Parc Cient&#xed;fic Barcelona, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merlos</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Welab Barcelona, Parc Cient&#xed;fic Barcelona, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vela</LastName><ForeName>Jos&#xe9; M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Welab Barcelona, Parc Cient&#xed;fic Barcelona, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrando-Grabulosa</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 01893 Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-9849-902X</Identifier><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 01893 Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RTI2018-096386-B-I00</GrantID><Agency>Ministerio de Ciencia, Innovaci&#xf3;n y Universidades of Spain</Agency><Country/></Grant><Grant><GrantID>CB06/05/1105</GrantID><Agency>CIBERNED</Agency><Country/></Grant><Grant><GrantID>FI-DGR 2017</GrantID><Agency>predoctoral fellowship of AGAUR, Departament d'Empresa i Coneixement de la Generalitat de Catalunya, cofounded by European Social Funds.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017480">Receptors, sigma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C106106">sigma-1 receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066829" MajorTopicYN="N">Neuroprotection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017480" MajorTopicYN="N">Receptors, sigma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SOD1G93A mice</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">motoneuron degeneration</Keyword><Keyword MajorTopicYN="N">sigma-1 receptor</Keyword><Keyword MajorTopicYN="N">spinal nerve injury</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. S.Y., R.F.R., J.B., A.M., M.M., and J.M.V. were employed by the company ESTEVE Pharmaceuticals at the time this study was performed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35743175</ArticleId><ArticleId IdType="pmc">PMC9223397</ArticleId><ArticleId IdType="doi">10.3390/ijms23126737</ArticleId><ArticleId IdType="pii">ijms23126737</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Edaravone (MCI-186) ALS 19 Study Group Safety and Efficacy of Edaravone in Well Defined Patients with Amyotrophic Lateral Sclerosis: A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A.C., Jesse S. Review: Evidence-Based Drug Treatment in Amyotrophic Lateral Sclerosis and Upcoming Clinical Trials. Ther. Adv. Neurol. Disord. 2009;2:319&#x2013;326. doi: 10.1177/1756285609336399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285609336399</ArticleId><ArticleId IdType="pmc">PMC3002601</ArticleId><ArticleId IdType="pubmed">21180622</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., Navarro X. Amyotrophic Lateral Sclerosis: Current Perspectives from Basic Research to the Clinic. Prog. Neurobiol. 2015;133:1&#x2013;26. doi: 10.1016/j.pneurobio.2015.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2015.07.004</ArticleId><ArticleId IdType="pubmed">26253783</ArticleId></ArticleIdList></Reference><Reference><Citation>Langa F., Codony X., Tovar V., Lavado A., Gim&#xe9;nez E., Cozar P., Cantero M., Dordal A., Hern&#xe1;ndez E., P&#xe9;rez R., et al. Generation and Phenotypic Analysis of Sigma Receptor Type I (&#x3a3;1) Knockout Mice. Eur. J. Neurosci. 2003;18:2188&#x2013;2196. doi: 10.1046/j.1460-9568.2003.02950.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.2003.02950.x</ArticleId><ArticleId IdType="pubmed">14622179</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavlyutov T.A., Epstein M.L., Andersen K.A., Ziskind-Conhaim L., Ruoho A.E. The Sigma-1 Receptor Is Enriched in Postsynaptic Sites of C-Terminals in Mouse Motoneurons. An Anatomical and Behavioral Study. Neuroscience. 2010;167:247&#x2013;255. doi: 10.1016/j.neuroscience.2010.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2010.02.022</ArticleId><ArticleId IdType="pmc">PMC2862368</ArticleId><ArticleId IdType="pubmed">20167253</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Saif A., Al-Mohanna F., Bohlega S. A Mutation in Sigma-1 Receptor Causes Juvenile Amyotrophic Lateral Sclerosis. Ann. Neurol. 2011;70:913&#x2013;919. doi: 10.1002/ana.22534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22534</ArticleId><ArticleId IdType="pubmed">21842496</ArticleId></ArticleIdList></Reference><Reference><Citation>Luty A.A., Kwok J.B.J., Dobson-Stone C., Loy C.T., Coupland K.G., Karlstr&#xf6;m H., Sobow T., Tchorzewska J., Maruszak A., Barcikowska M., et al. Sigma Nonopioid Intracellular Receptor 1 Mutations Cause Frontotemporal Lobar Degeneration-Motor Neuron Disease. Ann. Neurol. 2010;68:639&#x2013;649. doi: 10.1002/ana.22274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22274</ArticleId><ArticleId IdType="pubmed">21031579</ArticleId></ArticleIdList></Reference><Reference><Citation>Almendra L., Laranjeira F., Fern&#xe1;ndez-Marmiesse A., Negr&#xe3;o L. SIGMAR1 Gene Mutation Causing Distal Hereditary Motor Neuropathy in a Portuguese Family. Acta Myol. 2018;37:2&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6060428</ArticleId><ArticleId IdType="pubmed">30079398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ververis A., Dajani R., Koutsou P., Aloqaily A., Nelson-Williams C., Loring E., Arafat A., Mubaidin A.F., Horany K., Bader M.B., et al. Distal Hereditary Motor Neuronopathy of the Jerash Type Is Caused by a Novel SIGMAR1 c.500A&gt;T Missense Mutation. J. Med. Genet. 2020;57:178&#x2013;186. doi: 10.1136/jmedgenet-2019-106108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2019-106108</ArticleId><ArticleId IdType="pmc">PMC7042970</ArticleId><ArticleId IdType="pubmed">31511340</ArticleId></ArticleIdList></Reference><Reference><Citation>Brimson J.M., Brimson S., Chomchoei C., Tencomnao T. Using Sigma-Ligands as Part of a Multi-Receptor Approach to Target Diseases of the Brain. Expert Opin. Ther. Targets. 2020;24:1009&#x2013;1028. doi: 10.1080/14728222.2020.1805435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2020.1805435</ArticleId><ArticleId IdType="pubmed">32746649</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzm&#xe1;n-Lenis M.-S., Navarro X., Casas C. Selective Sigma Receptor Agonist 2-(4-Morpholinethyl)1-Phenylcyclohexanecarboxylate (PRE084) Promotes Neuroprotection and Neurite Elongation through Protein Kinase C (PKC) Signaling on Motoneurons. Neuroscience. 2009;162:31&#x2013;38. doi: 10.1016/j.neuroscience.2009.03.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2009.03.067</ArticleId><ArticleId IdType="pubmed">19345724</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono Y., Tanaka H., Takata M., Nagahara Y., Noda Y., Tsuruma K., Shimazawa M., Hozumi I., Hara H. SA4503, a Sigma-1 Receptor Agonist, Suppresses Motor Neuron Damage in in Vitro and in Vivo Amyotrophic Lateral Sclerosis Models. Neurosci. Lett. 2014;559:174&#x2013;178. doi: 10.1016/j.neulet.2013.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2013.12.005</ArticleId><ArticleId IdType="pubmed">24334165</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionescu A., Gradus T., Altman T., Maimon R., Saraf Avraham N., Geva M., Hayden M., Perlson E. Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model. Cell Death Dis. 2019;10:210. doi: 10.1038/s41419-019-1451-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1451-2</ArticleId><ArticleId IdType="pmc">PMC6397200</ArticleId><ArticleId IdType="pubmed">30824685</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., Oliv&#xe1;n S., Rando A., Casas C., Osta R., Navarro X. Sigma-1R Agonist Improves Motor Function and Motoneuron Survival in ALS Mice. Neurotherapeutics. 2012;9:814&#x2013;826. doi: 10.1007/s13311-012-0140-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-012-0140-y</ArticleId><ArticleId IdType="pmc">PMC3480575</ArticleId><ArticleId IdType="pubmed">22935988</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaja-Capdevila N., Hern&#xe1;ndez N., Navarro X., Herrando-Grabulosa M. Sigma-1 Receptor Is a Pharmacological Target to Promote Neuroprotection in the SOD1G93A ALS Mice. Front. Pharmacol. 2021;12:780588. doi: 10.3389/fphar.2021.780588.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.780588</ArticleId><ArticleId IdType="pmc">PMC8702863</ArticleId><ArticleId IdType="pubmed">34955848</ArticleId></ArticleIdList></Reference><Reference><Citation>Penas C., Pascual-Font A., Mancuso R., For&#xe9;s J., Casas C., Navarro X. Sigma Receptor Agonist 2-(4-Morpholinethyl)1 Phenylcyclohexanecarboxylate (Pre084) Increases GDNF and BiP Expression and Promotes Neuroprotection after Root Avulsion Injury. J. Neurotrauma. 2011;28:831&#x2013;840. doi: 10.1089/neu.2010.1674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2010.1674</ArticleId><ArticleId IdType="pubmed">21332255</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaja-Capdevila N., Hern&#xe1;ndez N., Zamanillo D., Vela J.M., Merlos M., Navarro X., Herrando-Grabulosa M. Neuroprotective Effects of Sigma 1 Receptor Ligands on Motoneuron Death after Spinal Root Injury in Mice. Int. J. Mol. Sci. 2021;22:6956. doi: 10.3390/ijms22136956.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22136956</ArticleId><ArticleId IdType="pmc">PMC8269081</ArticleId><ArticleId IdType="pubmed">34203381</ArticleId></ArticleIdList></Reference><Reference><Citation>Peviani M., Salvaneschi E., Bontempi L., Petese A., Manzo A., Rossi D., Salmona M., Collina S., Bigini P., Curti D. Neuroprotective Effects of the Sigma-1 Receptor (S1R) Agonist PRE-084, in a Mouse Model of Motor Neuron Disease Not Linked to SOD1 Mutation. Neurobiol. Dis. 2014;62:218&#x2013;232. doi: 10.1016/j.nbd.2013.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.10.010</ArticleId><ArticleId IdType="pubmed">24141020</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T., Su T.P. Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival. Cell. 2007;131:596&#x2013;610. doi: 10.1016/j.cell.2007.08.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.08.036</ArticleId><ArticleId IdType="pubmed">17981125</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrando-Grabulosa M., Gaja-Capdevila N., Vela J.M., Navarro X. Sigma 1 Receptor as a Therapeutic Target for Amyotrophic Lateral Sclerosis. Br. J. Pharmacol. 2021;178:1336&#x2013;1352. doi: 10.1111/bph.15224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15224</ArticleId><ArticleId IdType="pubmed">32761823</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng T.-Y., Tsai S.-Y.A., Su T.-P. Roles of Sigma-1 Receptors on Mitochondrial Functions Relevant to Neurodegenerative Diseases. J. Biomed. Sci. 2017;24:74. doi: 10.1186/s12929-017-0380-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-017-0380-6</ArticleId><ArticleId IdType="pmc">PMC5603014</ArticleId><ArticleId IdType="pubmed">28917260</ArticleId></ArticleIdList></Reference><Reference><Citation>Haga H., Matsuo K., Yabuki Y., Zhang C., Han F., Fukunaga K. Enhancement of ATP Production Ameliorates Motor and Cognitive Impairments in a Mouse Model of MPTP&#x2212;induced Parkinson&#x2019;s Disease. Neurochem. Int. 2019;129:104492. doi: 10.1016/j.neuint.2019.104492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2019.104492</ArticleId><ArticleId IdType="pubmed">31229554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H., Williams C., Etcheto A., Goodsaid F., Parmentier F., Sallantin J., Kaufmann W.E., Missling C.U., Afshar M. A Precision Medicine Framework Using Artificial Intelligence for the Identification and Confirmation of Genomic Biomarkers of Response to an Alzheimer&#x2019;s Disease Therapy: Analysis of the Blarcamesine (ANAVEX2-73) Phase 2a Clinical Study. Alzheimer&#x2019;s Dement. Transl. Res. Clin. Interv. 2020;6:e12013. doi: 10.1002/trc2.12013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12013</ArticleId><ArticleId IdType="pmc">PMC7167374</ArticleId><ArticleId IdType="pubmed">32318621</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilmann R., McGarry A., Grachev I.D., Savola J.M., Borowsky B., Eyal E., Gross N., Langbehn D., Schubert R., Wickenberg A.T., et al. Safety and Efficacy of Pridopidine in Patients with Huntington&#x2019;s Disease (PRIDE-HD): A Phase 2, Randomised, Placebo-Controlled, Multicentre, Dose-Ranging Study. Lancet Neurol. 2019;18:165&#x2013;176. doi: 10.1016/S1474-4422(18)30391-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30391-0</ArticleId><ArticleId IdType="pubmed">30563778</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., Zhu L., Liu D., Chi T., Ji X., Liu P., Yang X., Tian X., Zou L. Sigma-1 Receptor Protects against Endoplasmic Reticulum Stress-Mediated Apoptosis in Mice with Cerebral Ischemia/Reperfusion Injury. Apoptosis. 2019;24:157&#x2013;167. doi: 10.1007/s10495-018-1495-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10495-018-1495-2</ArticleId><ArticleId IdType="pubmed">30387007</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruna J., Videla S., Argyriou A.A., Velasco R., Villoria J., Santos C., Nadal C., Cavaletti G., Alberti P., Briani C., et al. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. Neurotherapeutics. 2018;15:178&#x2013;189. doi: 10.1007/s13311-017-0572-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-017-0572-5</ArticleId><ArticleId IdType="pmc">PMC5794691</ArticleId><ArticleId IdType="pubmed">28924870</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrando-Grabulosa M., Mulet R., Pujol A., Mas J.M., Navarro X., Aloy P., Coma M., Casas C. Novel Neuroprotective Multicomponent Therapy for Amyotrophic Lateral Sclerosis Designed by Networked Systems. PLoS ONE. 2016;11:e0147626. doi: 10.1371/journal.pone.0147626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0147626</ArticleId><ArticleId IdType="pmc">PMC4726541</ArticleId><ArticleId IdType="pubmed">26807587</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D., Jin L., Dykes-Hoberg M., Kuncl R.W. Chronic Inhibition of Glutamate Uptake Produces a Model of Slow Neurotoxicity. Proc. Natl. Acad. Sci. USA. 1993;90:6591&#x2013;6595. doi: 10.1073/pnas.90.14.6591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.14.6591</ArticleId><ArticleId IdType="pmc">PMC46978</ArticleId><ArticleId IdType="pubmed">8393571</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurice T. Bi-Phasic Dose Response in the Preclinical and Clinical Developments of Sigma-1 Receptor Ligands for the Treatment of Neurodegenerative Disorders. Expert Opin. Drug Discov. 2021;16:373&#x2013;389. doi: 10.1080/17460441.2021.1838483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2021.1838483</ArticleId><ArticleId IdType="pubmed">33070647</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadi&#x107; V., Malci A., Goldhammer N., Stubendorff B., Sengupta S., Prell T., Keiner S., Liu J., Guenther M., Frahm C., et al. Sigma 1 Receptor Activation Modifies Intracellular Calcium Exchange in the G93AhSOD1 ALS Model. Neuroscience. 2017;359:105&#x2013;118. doi: 10.1016/j.neuroscience.2017.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2017.07.012</ArticleId><ArticleId IdType="pubmed">28723387</ArticleId></ArticleIdList></Reference><Reference><Citation>Koliatsos V.E., Price W.L., Pardo C.A., Price D.L. Ventral Root Avulsion: An Experimental Model of Death of Adult Motor Neurons. J. Comp. Neurol. 1994;342:35&#x2013;44. doi: 10.1002/cne.903420105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.903420105</ArticleId><ArticleId IdType="pubmed">8207127</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia J., Cheng J., Wang C., Zhen X. Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases. Front. Cell. Neurosci. 2018;12:314. doi: 10.3389/fncel.2018.00314.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00314</ArticleId><ArticleId IdType="pmc">PMC6158303</ArticleId><ArticleId IdType="pubmed">30294261</ArticleId></ArticleIdList></Reference><Reference><Citation>Brites D., Vaz A.R. Microglia Centered Pathogenesis in ALS: Insights in Cell Interconnectivity. Front. Cell. Neurosci. 2014;8:117. doi: 10.3389/fncel.2014.00117.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00117</ArticleId><ArticleId IdType="pmc">PMC4033073</ArticleId><ArticleId IdType="pubmed">24904276</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipi T., Hermanova Z., Tureckova J., Vanatko O., Anderova M. Glial Cells&#x2014;The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. J. Clin. Med. 2020;9:261. doi: 10.3390/jcm9010261.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9010261</ArticleId><ArticleId IdType="pmc">PMC7020059</ArticleId><ArticleId IdType="pubmed">31963681</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M., Harlan B.A., Killoy K.M., Vargas M.R. Role and Therapeutic Potential of Astrocytes in Amyotrophic Lateral Sclerosis. Curr. Pharm. Des. 2017;23:5010. doi: 10.2174/1381612823666170622095802.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612823666170622095802</ArticleId><ArticleId IdType="pmc">PMC5740017</ArticleId><ArticleId IdType="pubmed">28641533</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerver&#xf3; C., Blasco A., Tarabal O., Casanovas A., Piedrafita L., Navarro X., Esquerda J.E., Calder&#xf3; J. Glial Activation and Central Synapse Loss, but Not Motoneuron Degeneration, Are Prevented by the Sigma-1 Receptor Agonist PRE-084 in the Smn2B/- Mouse Model of Spinal Muscular Atrophy. J. Neuropathol. Exp. Neurol. 2018;77:577&#x2013;597. doi: 10.1093/jnen/nly033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nly033</ArticleId><ArticleId IdType="pubmed">29767748</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;az J.L., Cuevas F., Oliva A.I., Font D., Sarmentero M.&#xc1;., &#xc1;lvarez-Bercedo P., L&#xf3;pez-Valbuena J.M., Peric&#xe0;s M.A., Enrech R., Montero A., et al. Tricyclic Triazoles as &#x3c3; 1 Receptor Antagonists for Treating Pain. J. Med. Chem. 2021;64:5157&#x2013;5170. doi: 10.1021/acs.jmedchem.1c00244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c00244</ArticleId><ArticleId IdType="pubmed">33826322</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega-Roldan J.L., Ossa F., Schnell J.R. Characterization of the Human Sigma-1 Receptor Chaperone Domain Structure and Binding Immunoglobulin Protein (BiP) Interactions. J. Biol. Chem. 2013;288:21448&#x2013;21457. doi: 10.1074/jbc.M113.450379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.450379</ArticleId><ArticleId IdType="pmc">PMC3774411</ArticleId><ArticleId IdType="pubmed">23760505</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf2;dol-Caballero G., Santos D., Navarro X., Herrando-Grabulosa M. Neuregulin 1 Reduces Motoneuron Cell Death and Promotes Neurite Growth in an in Vitro Model of Motoneuron Degeneration. Front. Cell. Neurosci. 2017;11:431. doi: 10.3389/fncel.2017.00431.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00431</ArticleId><ArticleId IdType="pmc">PMC5767462</ArticleId><ArticleId IdType="pubmed">29375317</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., Oliv&#xe1;n S., Mancera P., Past&#xe9;n-Zamorano A., Manzano R., Casas C., Osta R., Navarro X. Effect of Genetic Background on Onset and Disease Progression in the SOD1-G93A Model of Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. 2012;13:302&#x2013;310. doi: 10.3109/17482968.2012.662688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.662688</ArticleId><ArticleId IdType="pubmed">22424126</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., Santos-Nogueira E., Osta R., Navarro X. Electrophysiological Analysis of a Murine Model of Motoneuron Disease. Clin. Neurophysiol. 2011;122:1660&#x2013;1670. doi: 10.1016/j.clinph.2011.01.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2011.01.045</ArticleId><ArticleId IdType="pubmed">21354365</ArticleId></ArticleIdList></Reference><Reference><Citation>Miana-Mena F.J., Mu&#xf1;oz M.J., Yag&#xfc;e G., Mendez M., Moreno M., Ciriza J., Zaragoza P., Osta R. Optimal methods to characterize the G93A mouse model of ALS. Amyotroph. Lateral Scler. 2005;6:55&#x2013;62. doi: 10.1080/14660820510026162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820510026162</ArticleId><ArticleId IdType="pubmed">16036427</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>